Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.

By H. Ohgaki, P. Kleihues. Journal of Neuropathology and Experimental Neurology, 2005

1,375 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/685387ae94ec5c86ac390268b5fb8887eaee1dce

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Molecular Biology

Citations in the corpus

The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS) (2015, background): “2377694 two years or less and require immediate treatment [2], [3].”
The Definition of Primary and Secondary Glioblastoma (2012, methodology): “Switzerland, using clinical criteria and histopathologic evidence, only 5% of all glioblastomas diagnosed were secondary (7, 63).”
Immunotherapy for glioma: current management and future application. (2020, neutral): “The 10-year survival rate in low-grade glioma is 47% with a median survival time of 11.6 years [4].”
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary (2016, background): “Historically, the prognostic differences between WHO grade II diffuse astrocytomas and WHO grade III anaplastic astrocytomas were highly significant [31].”
The transcriptional network for mesenchymal transformation of brain tumors (2009, methodology): “We sought to establish (1) whether MRs inferred by our procedure would also be inferred when using an independent glioma sample data set, and (2) whether MRs identified on the basis of clinical outcome would overlap significantly with those inferred from MGES analysis.”
Genetic pathways to primary and secondary glioblastoma. (2007, background): “The mean age of primary glioblastoma patients was 62 years, whereas secondary glioblastomas developed in younger patients (45 years).(5,6) At a population level, primary glioblastomas developed more frequently in men (male to female ratio, 1:33), whereas secondary glioblastomas were more frequent in”
IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas (2009, background): “During the past decade, evidence has accumulated that primary and secondary glioblastomas constitute distinct disease entities that affect patients of different age, develop through different genetic pathways (1, 2), show different RNA and protein expression profiles (11–13), and may differ in their”
Long-term survival with glioblastoma multiforme. (2007, background): “45, corresponding to a proportion of female patients of 43 and 41%, respectively (Barnholtz-Sloan et al., 2003; Ohgaki and Kleihues 2005).”